Cost-effectiveness of subcutaneous ketamine in the management of chronic cancer pain

Nicola McCaffrey, Thomas Flint, Billingsley Kaambwa, Belinda Fazekas, David Currow, Janet Hardy, Meera Agar, Simon Eckermann

    Research output: Contribution to conferencePaperpeer-review


    Study implications:
    –No statistically significant difference in responder rates but higher toxicity and worse QOL
    –Higher ketamine costs despite lower costs for other medications
    –When costs and QOL are jointly considered, ketamine is neither effective nor cost-effective
    Original languageEnglish
    Number of pages23
    Publication statusPublished - May 2015
    Event13th Australian Palliative Care Conference Melbourne: Fit for the future - Melbourne Convention and Exhibition Centre, Melbourne, Australia
    Duration: 1 Sept 20154 Sept 2015
    Conference number: 13


    Conference13th Australian Palliative Care Conference Melbourne


    • End-of-life care
    • palliative medicine
    • ketamine
    • pain management

    Cite this